Finland's Tamro Group sales reached 10.43 billion markka ($2.3 billion) for the 10-month period January-October, 1996, an increase of 20% on the like, year-earlier figure. The strengthening Swedish krona had an effect of around nine percentage points on the growth.
Total sales of the pharmaceutical distribution division grew 21% to 9.71 billion markka, and the market share of sales of pharmaceuticals was 62% (compared with 61% in the like, 1995 period) in Finland for the 10 months and 62% (63%) in Sweden (for January through September). Sales of the hospital and laboratory division for the 10 months were 442 million markka, a rise of 19%. Company acquisitions contributed around nine percentage points to the sales increase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze